http://hdl.handle.net/2027.42/39193 Search the Channel search http://deepblue.lib.umich.edu/simple-search http://hdl.handle.net/2027.42/51542 Title: SLN Biopsy for Melanoma: Therapeutic Procedure or Diagnostic Test? <br/> <br/>Authors: Vemuri, Chandu; Sabel, Michael S. <br/> <br/>Abstract: Although SLN biopsy is considered standard of care by many surgical oncologists and dermatologists, it remains controversial among others. Clinical practitioners in both surgery and dermatology have used the same available evidence to both support and refute the sentinel lymph node hypothesis and the role SLN biopsy should play in the management of cutaneous melanoma. Much of this disagreement centers on whether one views SLN biopsy as a therapeutic intervention meant to improve survival or a diagnostic test meant to stratify risk and select patients for further therapy. This article will review the available data, including the most recent data from the MSLT-I trial, the first prospective randomized study of SLN biopsy in melanoma. http://hdl.handle.net/2027.42/51541 Title: Surgical Therapy of Cutaneous Melanoma <br/> <br/>Authors: Blazer, Dan; Sondak, Vernon K.; Sabel, Michael S. <br/> <br/>Abstract: For most solid tumors, therapy has evolved from surgery alone to a multidisciplinary approach. Malignant melanoma remains an exception, with surgery maintaining the principal role not only for treatment of the primary lesion but also staging and the management of advanced disease. The surgical management of melanoma has evolved over the years, resulting in a substantial decrease in the morbidity associated with treatment wihtout a compromise in outcome. This article will review the changes that have occured leading to the current surgical approach to melanoma, the evidence behind these recommendations, and new questions that need to be addressed. http://hdl.handle.net/2027.42/41267 Title: The role of the surgeon in the management of melanoma. <br/> <br/>Authors: Sabel, Michael S.; Arora, Alisha <br/> <br/>Abstract: While multimodality therapy has become the standard for most solid tumors, the mainstay of therapy for melanoma remains surgical. This includes not only early stage disease, but advanced melanoma as well. The surgical approach to melanoma has changed dramatically, with a trend towards less aggressive resection of the primary tumor, and towards a more aggressive approach to regional and metastatic disease. Melanoma surgery has been altered by our knowledge of the biology of the disease, and the results of well-designed, prospective randomized trials. Conversely, new surgical approaches have expanded our understanding of melanoma biology, and new randomized trials are needed to further define the optimal surgical approach. This article will review the evolution of melanoma surgery and the evidence behind today's recommendations. http://hdl.handle.net/2027.42/41266 Title: Locoregional therapy of breast cancer: maximizing control, minimizing morbidity <br/> <br/>Authors: Sabel, Michael S. <br/> <br/>Abstract: The goal of locoregional therapy in breast cancer has remained unchanged for a century: the eradication of all malignant cells from the breast and draining lymph nodes, hopefully prior to them having spread to distant organs. However, how we accomplish this goal has changed dramatically over this time period and our success in acheiving this goal has been greatly enhanced by improvements in breast imaging and systemic therapies. The therapeutic importance of surgery and radiation has been underestimated in recent years and thought to have minimal impact on long-term outcome. More recent data have reputed this contention and the relationship between local control and survival in breast cancer is becoming increasingly apparent. This article will review the importance of attaining optimum local control with minimum morbidity and examine where the future of locoregional therapy of breast cancer may lie.